Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/25/2869488/0/en/BioXcel-Therapeutics-to-Report-First-Quarter-2024-Financial-Results-on-May-9-2024.html
https://www.globenewswire.com/news-release/2024/04/24/2868783/0/en/BioXcel-Therapeutics-Announces-Late-Breaking-Abstract-on-Preliminary-Findings-from-Phase-2-Investigator-Sponsored-Trial-of-BXCL701-and-KEYTRUDA-in-Metastatic-Pancreatic-Ductal-Aden.html
https://www.globenewswire.com/news-release/2024/04/22/2866727/0/en/BioXcel-Therapeutics-Announces-Plan-for-Evaluating-BXCL501-in-the-At-Home-Setting-to-Expand-Its-Market-Potential.html
https://www.globenewswire.com/news-release/2024/04/10/2860623/0/en/BioXcel-Therapeutics-Announces-TRANQUILITY-In-Care-Pivotal-Phase-3-Trial-Plan-With-BXCL501-for-Agitation-Associated-With-Alzheimer-s-Dementia.html
https://www.globenewswire.com/news-release/2024/03/25/2851487/0/en/BioXcel-Therapeutics-Announces-25-Million-Registered-Direct-Offering.html
https://www.globenewswire.com//news-release/2024/03/15/2846944/0/en/BioXcel-Therapeutics-Announces-European-Patent-Office-s-Grant-of-Patent-for-Method-of-Treating-Agitation-in-Dementia-Using-Sublingual-Dexmedetomidine.html
https://www.globenewswire.com//news-release/2024/03/12/2844387/0/en/BioXcel-Therapeutics-Reports-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2023.html
https://www.globenewswire.com//news-release/2024/03/01/2838717/0/en/BioXcel-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-12-2024.html
https://www.globenewswire.com//news-release/2024/02/13/2828330/0/en/BioXcel-Therapeutics-Announces-Termination-of-Proposed-Public-Offering.html
https://www.globenewswire.com//news-release/2024/02/12/2827423/0/en/BioXcel-Therapeutics-Receives-FDA-Fast-Track-Designation-for-BXCL701-for-Treatment-of-Small-Cell-Neuroendocrine-Prostate-Cancer-SCNC.html